Cantor Fitzgerald Reiterates Overweight on Mirum Pharmaceuticals, Maintains $40 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Josh Schimmer has reiterated an Overweight rating on Mirum Pharmaceuticals (NASDAQ:MIRM) and maintained a $40 price target.

May 09, 2024 | 2:25 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald maintains an Overweight rating and a $40 price target on Mirum Pharmaceuticals.
The reiteration of an Overweight rating and maintenance of a $40 price target by a reputable analyst like Josh Schimmer suggests a positive outlook on Mirum Pharmaceuticals' stock. This endorsement could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100